PureTech Health (LON:PRTC) Share Price Breaks Below 50-Day Moving Average – Should You Sell?

PureTech Health plc (LON:PRTC)’s share price passed below its 50-day moving average during trading on Monday. The stock has a 50-day moving average of GBX 117.59 and traded as low as GBX 112. PureTech Health shares last traded at GBX 115.40, with a volume of 272,872 shares.

Wall Street Analyst Weigh In

Separately, Peel Hunt reiterated a “buy” rating and set a GBX 508 price target on shares of PureTech Health in a report on Monday, July 13th. One research analyst has rated the stock with a Buy rating. According to MarketBeat, PureTech Health presently has a consensus rating of “Buy” and a consensus price target of GBX 508.

PureTech Health Stock Performance

The business has a fifty day moving average of GBX 117.49 and a 200-day moving average of GBX 123.32. The company has a market cap of £280.49 million, a PE ratio of -2.34 and a beta of 0.77. The company has a current ratio of 4.60, a quick ratio of 2.51 and a debt-to-equity ratio of 4.78.

Insider Transactions at PureTech Health

In other PureTech Health news, insider Robert Langer bought 93,944 shares of PureTech Health stock in a transaction dated Wednesday, July 29th. The shares were purchased at an average cost of GBX 1 per share, with a total value of £939.44. Also, insider Michele Holcomb bought 93,944 shares of PureTech Health stock in a transaction dated Wednesday, July 29th. The shares were acquired at an average cost of GBX 1 per share, for a total transaction of £939.44. In the last quarter, insiders purchased 469,720 shares of company stock worth $469,720. Corporate insiders own 13.31% of the company’s stock.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.